Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYN-5356 in Cognitive Impairment Associated With Schizophrenia
NCT07191483Phase 2Completed
- Sponsor
- Kynexis
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KYN-5356 in schizophrenia, sponsored by Kynexis. Started Aug 2025; status: completed.
02
Drugs
KYN-5356
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07191483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191483.